Life Sciences

Brillio’s agentic AI accelerators automate hypothesis generation, biomarker identification, and molecular profiling, enabling research teams to uncover novel therapeutic opportunities with greater speed and precision. By embedding domain-trained agents across early discovery workflows, Brillio helps life sciences organizations achieve a 30% reduction in drug discovery operational costs while maintaining scientific rigor and compliance standards.

ADAM (Agentic Data and Application Management) is Brillio’s flagship AI platform that brings together modular agent libraries, blueprint libraries, and reusable AI assets specifically tuned for molecule-to-market impact. Life sciences enterprises using ADAM benefit from 3x faster delivery, with domain-trained agents embedded across research, clinical, regulatory, and commercial workflows to accelerate every stage from target discovery through launch readiness.

Brillio’s patient screening accelerators use precise AI-driven workflows that match eligible patients to trials by drawing on EHR data, genomics, and social determinants of health. This approach reduces recruitment timelines and improves enrollment accuracy, helping clinical operations teams address one of the most persistent bottlenecks in trial execution.

Brillio’s Decentralized Trials Acceleration capability streamlines remote monitoring, electronic consent, and virtual site operations through purpose-built agentic workflows, enabling scalable, patient-centric trials with improved diversity and retention. For clinical operations leaders, this means greater geographic reach and reduced dependency on traditional site infrastructure, without sacrificing oversight or compliance.

Brillio builds GxP and 21 CFR Part 11 compliance directly into its AI architecture through an AI-first SDLC infused with observability, auditability, and lifecycle governance. Its PHI-safe infrastructure and ADAM-powered solutions are designed for global regulatory environments, giving life sciences enterprises the enterprise-grade assurance they need to deploy AI confidently in regulated workflows.

Brillio embeds agentic AI across the existing technology stacks that pharma and life sciences enterprises already rely on, including Veeva, Salesforce, Snowflake, Adobe, ServiceNow, and Databricks. This deep platform integration ensures that AI capabilities for clinical research, commercial operations, and patient engagement are delivered seamlessly rather than as isolated point solutions.

Life sciences enterprises working with Brillio have achieved a 72% increase in customer engagement with AI, a 33% improvement in time to therapy, and recipe authoring time reduced from 60 hours to 1.2 hours. These outcomes reflect Brillio’s ability to deliver quantifiable, cross-functional impact across both R&D and commercial operations using adaptive AI agents and purpose-built accelerators.

Brillio’s cross-functional AI-native squads, trained in GenAI, prompt engineering, and agent design, bring both scientific and engineering depth to every stage of the life sciences value chain, from early discovery through regulatory submissions and commercial launch. By combining GenAI copilots with modular agent libraries, Brillio’s consulting approach operationalizes intelligence across R&D, safety, medical affairs, and commercial operations as a unified, continuous workflow.